Work

Outcome of COVID-19 infection in cancer patients during active systemic anticancer treatment. Single-institution experience. A retrospective analysis

Year: 2021
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Patients with cancer undergoing active systemic anticancer treatment (chemotherapy, immunotherapy, targeted, or combination therapy) are at greater risk of COVID-19 infection than persons without cancer. In this paper, the authors analyse the spread of the coronavirus among cancer patients undergoing systemic therapy, and the impact of COVID-19 infection on the continuation of cancer treatment and its outcome at one community hospital in a mid-sized city in the south of Poland. MATERIAL AND METHODS: < 0.05. RESULTS: = 0.005. The fatality rate was 27.3% in cancer patients undergoing active anticancer therapy, compared to 3% in the general Polish population. Neither heparin nor G-CSF use had any influence on COVID-19 infection. CONCLUSIONS: = 0.005), and this was attributable to individual behaviour.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $215
OpenAlex ID: W3202200296
FWCI: 0.191
Cites: 17
Cited by: 4
Related to: 10